H. Lundbeck A/S
Clinical trials sponsored by H. Lundbeck A/S, explained in plain language.
A pharmaceutical company focused on brain diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for teens with chronic migraines? Results expected Sep 2026 (estimated)
- New hope for rare hormone disorder: drug targets Out-of-Control cortisol Results expected Sep 2026 (estimated)
- New infusion drug hopes to tame rare hormone disorder Results expected Sep 2026 (estimated)
- Can a new drug play well with others? a trial puts it to the test Results expected Nov 2026 (estimated)
- New narcolepsy drug enters first human safety tests Results expected Feb 2027 (estimated)
-
New drug aims to cut migraine days in kids by half
Disease control Recruiting nowThis study tests whether eptinezumab, given through a vein, can safely reduce the number of migraine days in children and teens aged 6 to 17 with episodic migraine. Participants receive either the drug or a placebo, and researchers track monthly migraine days over 12 weeks. The g…
Phase 3 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
New hope for rare hormone disorder: drug targets Out-of-Control cortisol
Disease control Recruiting nowThis study tests a new drug called Lu AG13909 in 18 adults with Cushing's disease, a rare condition where the body produces too much cortisol. The goal is to see if the drug can safely lower cortisol levels to normal. Participants will receive the drug through an IV or injection,…
Phase 2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for teens with chronic migraines?
Disease control Recruiting nowThis study tests whether eptinezumab, given as an IV infusion, can reduce the number of migraine days in adolescents aged 12 to 17 who have chronic migraine (15 or more headache days per month). Participants will receive either the drug or a placebo (salt water) and track their h…
Phase 3 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New Parkinson's drug candidate enters first safety tests in china
Disease control Recruiting nowThis early-stage trial will test the safety and tolerability of a new oral drug called Lu AF28996 in 10 Chinese adults with Parkinson's disease. Participants will take the drug and be monitored for side effects and how the body processes it. The study is not yet recruiting and do…
Phase 1 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Migraine drug vyepti tested in kids for long-term safety
Disease control Recruiting nowThis study tests the long-term safety of eptinezumab (Vyepti) in 600 children and teens aged 6 to 17 with chronic or episodic migraine. Participants must have completed a prior study. The main goal is to track side effects over time, with additional measures of drug levels and im…
Phase 3 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New infusion drug hopes to tame rare hormone disorder
Disease control Recruiting nowThis early-stage trial is testing a new drug called Lu AG13909 in 42 adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that disrupts hormone production. The study aims to check the drug's safety, how it moves through the body, and its effects on hormone l…
Phase 1/2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Parkinson's pill aims to cut 'OFF' time and ease daily struggles
Symptom relief Recruiting nowThis Phase 2 trial tests whether adding Lu AF28996 to standard Parkinson's medications can extend the time patients feel their movement symptoms are well-controlled (called 'good ON time'). About 150 adults with Parkinson's who still experience motor fluctuations despite optimize…
Phase 2 • Sponsor: H. Lundbeck A/S • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New narcolepsy drug enters first human safety tests
Symptom relief Recruiting nowThis early-stage trial is testing a new drug called Lu AH69593 to see if it is safe and how the body handles it. The study includes healthy volunteers and people with narcolepsy. Researchers will monitor side effects and measure drug levels in the blood, including how food affect…
Phase 1 • Sponsor: H. Lundbeck A/S • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC